These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 2222559)

  • 1. Pharmacokinetics of iopamidol in adults with renal failure.
    Corradi A; Menta R; Cambi V; Maccarini P; Cerutti R
    Arzneimittelforschung; 1990 Jul; 40(7):830-2. PubMed ID: 2222559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of iopamidol 370 in infants and children during ivp.
    Beluffi G; Cerutti R; Fiori P; Martini A
    Radiol Med; 1989 May; 77(5):493-5. PubMed ID: 2748960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cefotaxime after a single intravenous dose in patients with impaired renal function.
    Moukhtar I; Nawishy S; Sabbour M
    Chemioterapia; 1987 Feb; 6(1):38-40. PubMed ID: 3829135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clearance of iopamidol, a non-ionic contrast medium, by CAPD in patients with end-stage renal failure.
    Donnelly PK; Burwell N; McBurney A; Ward JW; Walls J; Watkin EM
    Br J Radiol; 1992 Dec; 65(780):1108-13. PubMed ID: 1286420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of a single oral dose of ofloxacin in patients with renal failure.
    Nawishy S; Moukhtar I; Sabbour M
    Chemioterapia; 1986 Dec; 5(6):391-3. PubMed ID: 3467875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition kinetics of dibekacin in normal subjects and in patients with renal failure.
    Arancibia A; Chávez J; Ibarra R; Ruiz I; Icarte A; Thambo S; Chávez H
    Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):38-43. PubMed ID: 3557728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of mecillinam after a single intravenous dose in patients with impaired renal function.
    Moukhtar I; Nawishy S; Sabbour M
    Int J Clin Pharmacol Res; 1987; 7(1):59-62. PubMed ID: 3583488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and dose recommendations of carumonam in renal failure.
    Koeppe P; Höffler D; Strobel K
    Arzneimittelforschung; 1987 Jan; 37(1):65-9. PubMed ID: 3566860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Butofilolol pharmacokinetics in chronic renal insufficiency.
    Jeanniot JP; Houin G; Ledudal P; Cautreels W; Giudicelli CP; Tillement JP
    Int J Clin Pharmacol Res; 1984; 4(3):165-73. PubMed ID: 6149194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetics of cefotaxime in patients with chronic renal impairment (author's transl)].
    Fillastre JP; Ings RM; Leroy A; Humbert G; Godin M
    Nouv Presse Med; 1981 Feb; 10(8):574-9. PubMed ID: 6259595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of vancomycin in patients with severely impaired renal function.
    Gonzalez-Martin G; Acuna V; Perez C; Labarca J; Guevara A; Tagle R
    Int J Clin Pharmacol Ther; 1996 Feb; 34(2):71-5. PubMed ID: 8929749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition kinetics of dibekacin in patients with renal failure and in patients undergoing hemodialysis.
    Arancibia A; Baillarie D; Bravo M; Chávez J
    Int J Clin Pharmacol Ther; 1995 Nov; 33(11):623-7. PubMed ID: 8688988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.
    Rey E; d'Athis P; Richard MO; Fillastre JP; Olive G
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):648-52. PubMed ID: 6526539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of ceftizoxime in renal failure patients without dialysis.
    Li P; Cai Q; Gao S; Liu GL; Cui RL; Yang XY
    Zhongguo Yao Li Xue Bao; 1995 Sep; 16(5):402-4. PubMed ID: 8701753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of iopentol in patients with chronic renal failure.
    Svaland MG; Kolmannskog F; Lillevold PE; Nordal KP; Ressem L; Berg KJ
    Acta Radiol; 1992 Sep; 33(5):482-4. PubMed ID: 1389660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of digoxin in Nigerians.
    Iyun AO; Lukanbi FA
    Afr J Med Med Sci; 1988 Mar; 17(1):9-15. PubMed ID: 2834936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.
    Teichert J; Tuemmers T; Achenbach H; Preiss C; Hermann R; Ruus P; Preiss R
    J Clin Pharmacol; 2005 Mar; 45(3):313-28. PubMed ID: 15703366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia.
    Usui T; Oiso Y; Tomita A; Ogata E; Uchida T; Ikeda K; Watanabe T; Higuchi S
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):239-44. PubMed ID: 9208339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.